
Beware of Sarepta, CRISPR Therapeutics, and More
[ad_1] Investors should be wary of biotech stocks. Sarepta Therapeutics (SRPT) lost 21.45% yesterday and lost nearly 70% of its value in 2025. The company lost $3.42 a share, despite revenue growing by 80.1% Y/Y to $744.9 million. Sarepta management eroded investor returns when it cut its revenue forecast for this year. Costs…